Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Gross Margin of 88.09% for Q1 2026, down 75.0% year-over-year from 352.38% in Q1 2025, and down 3.84% quarter-over-quarter from 91.61% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Gross Margin for 6 consecutive years, with 88.09% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 75.0% year-over-year to 88.09%; the TTM figure through Mar 2026 stood at 89.41% (down 21.0% YoY), while the FY2025 annual figure was 89.73%, changed 0.0% from the prior year.
- Gross Margin slipped to 88.09% in Q1 2026 per RYTM's latest filing, from 91.61% in the prior quarter.
- Across five years, Gross Margin topped out at 112.77% in Q4 2022 and bottomed at 84.65% in Q1 2022.
- Historically, Gross Margin has averaged 90.5% across 5 years, with a median of 88.85% in 2025.
- Annual changes were most pronounced in 2022 — Gross Margin surged 4583 bps — and 2023, when it slumped 2611 bps.
- Rhythm Pharmaceuticals' Gross Margin stood at 112.77% in 2022, then decreased by 23 bps to 86.66% in 2023, then increased by 5 bps to 90.95% in 2024, then climbed by 1 bps to 91.61% in 2025, then declined by 4 bps to 88.09% in 2026.
- Business Quant data shows RYTM's Gross Margin at 88.09% in Q1 2026, 91.61% in Q4 2025, and 89.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 87.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.47% |
| Mar 31, 2026 | 88.09% |
| Dec 31, 2025 | 91.61% |
| Sep 30, 2025 | 89.28% |
| Jun 30, 2025 | 88.57% |
| Mar 31, 2025 | 88.85% |
| Dec 31, 2024 | 90.95% |
| Sep 30, 2024 | 88.49% |
| Jun 30, 2024 | 89.87% |
| Mar 31, 2024 | 89.19% |
| Dec 31, 2023 | 86.66% |
| Sep 30, 2023 | 89.28% |
| Jun 30, 2023 | 88.37% |
| Mar 31, 2023 | 87.61% |
| Dec 31, 2022 | 112.77% |
| Sep 30, 2022 | 88.40% |
| Jun 30, 2022 | 95.83% |
| Mar 31, 2022 | 84.65% |
| Dec 31, 2021 | 87.01% |
| Sep 30, 2021 | 78.40% |